DONGGUAN, GUANGDONG, CHINA, January 13, 2026 /EINPresswire.com/ -- As healthcare increasingly shifts towards at-home ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

Xenon Pharmaceuticals Inc. Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026. Five additional Phase 3 azetu ...

Risk factors for suicide attempt (SA) and suicide may have overlapping phenotypes that are related yet have distinct outcomes, which can inform screening practices, risk prediction, and prevention, ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Trends for medical device manufacturers in 2026 include balancing sustainability costs, flexible automation, AI-driven ...

There is plenty of opportunity for medtech manufacturers in Asia, but first you need to know how to avoid costly pitfalls.

As 2026 begins, the good news is that Medtronic hasn't peaked yet. There are still solid reasons to consider buying shares of ...

Questions about cost and patient benefit loom as Congress considers automatic Medicare coverage for 'breakthrough' medical ...

Neurolief announced today that the FDA granted approval for its Proliv Rx at-home neuromodulation therapy for treating ...